1 / 8

Strategic Analysis of the Ibrutinib Market

The Ibrutinib Market size is expected to reach USD 58.70 billion, registering a CAGR of 23.1% by 2030.

Sanyukta2
Download Presentation

Strategic Analysis of the Ibrutinib Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ibrutinib Market The Ibrutinib Market size is expected to reach USD 58.70 billion registering a CAGR of 23.1% from 2022 to 2030 Next Move Strategy Consulting

  2. Agenda • Market Overview • Market Segmentation • Regional Analysis • Key Market Players • Key Highlights Next Move Strategy Consulting

  3. Market Overview • Ibrutinib is a chemical substance that is sold under the brand name Imbruvica. • It belongs to a class of medications called kinase inhibitors. It helps to retard the spread • of cancerous cells by blocking the action of abnormal proteins. • It is used to treat chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia. It is also considered for second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft. • The demand for ibrutinib had increased due to rising number of cancer patients across the world along with the increasing development of healthcare infrastructure related to cancer. Ibrutinib can be used to treat different types of blood cancer including Leukemia, Lymphoma and Myeloma. • Several market players such as Johnson and Johnson, Pfizer and Bluepharma are involved in development of generic drugs for treatment of cancer that is also expected to drive the growth of the ibrutinib market. Next Move Strategy Consulting

  4. Market Segmentation • By Product Type • 140 mg • 10 mg • 5 mg • By Application • Chronic Lymphocytic Leukemia (CLL) • Mantle Cell Lymphoma (MCL) • Diffuse Large B Cell Lymphoma (DLBCL) • Multiple Myeloma (MM) • Follicular Lymphoma (FL) Next Move Strategy Consulting

  5. Regional Analysis • North America • U.S • Canada • Mexico • Asia-Pacific • China • India • Japan • South Korea • Australia • Rest of Asia-Pacific • RoW • UAE • Saudi Arabia • South Africa • Brazil • Remaining Countries • Europe • The UK • Germany • France • Italy • Spain • Denmark • Netherlands • Finland • Sweden • Norway • Russia Next Move Strategy Consulting

  6. Key Market Players • Beacon Pharmaceuticals • Janssen Pharmaceuticals • Zydus Cadila • Pharmacyclics Inc. • Johnson and Johnson • Incepta Pharmaceuticals • Bluepharma • ABBVie • 3M • Physicians Total Care • Graceway Pharmaceuticals Next Move Strategy Consulting

  7. Key Highlights • Market Growth : The ibrutinib market has been experiencing significant • growth due to its efficacy in treating certain types of hematologic • malignancies, including chronic lymphocytic leukemia (CLL), mantle • cell lymphoma (MCL), and Waldenström’s macroglobulinemia. • Mechanism of Action : Ibrutinib is a Bruton's tyrosine kinase (BTK) • inhibitor that works by blocking the signals that help cancer cells grow and survive. This • mechanism has proven effective in treating various blood cancers. • Approved Indications : Ibrutinib is approved for multiple indications, including CLL, MCL, small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL). Its versatility in treating different cancers contributes to its market growth. • Market Leaders : Ibrutinib is marketed under the brand name Imbruvica by AbbVie and Janssen Pharmaceuticals. It was one of the first BTK inhibitors to receive approval, and its brand recognition contributes to its leading position in the market. Next Move Strategy Consulting

  8. THANK YOU Next Move Strategy Consulting Follow us www.nextmsc.com info@nextmsc.com +1-217-650-7991 Access Full Report - https://www.nextmsc.com/report/ibrutinib-market Next Move Strategy Consulting

More Related